Promising Test Reveals Possible Correlation between Diet of Red Meat and Increased Cancer Risk

Strategic Insights -

A groundbreaking study published online in Cancer Research may revolutionize the detection and treatment of cancer in humans. The research, led by UC San Diego researchers, found a possible correlation between the diet of red meat and increased cancer risk, utilizing a non-human sugar molecule (Neu5Gc) commonly found in people through their diet. A blood test of antibodies to one specific Neu5Gc-containing sugar chain could diagnose breast cancer as effectively as the standard PSA test for prostate cancer. The study also discovered that introducing purified human anti-Neu5Gc antibodies may have immunotherapeutic potential, specifically killing Neu5Gc-expressing mouse or human tumors.

Key Takeaways:

  • The study discovered a possible correlation between the diet of red meat and increased cancer risk, utilizing a non-human sugar molecule (Neu5Gc) commonly found in people through their diet.
  • A blood test of antibodies to one specific Neu5Gc-containing sugar chain could diagnose breast cancer as effectively as the standard PSA test for prostate cancer.
  • The study found that introducing purified human anti-Neu5Gc antibodies may have immunotherapeutic potential, specifically killing Neu5Gc-expressing mouse or human tumors.
  • Researchers sampled 385 human blood samples and discovered that patients with carcinomas have elevated levels of antibodies to one specific Neu5Gc-containing sugar chain that incorporates into the cancer marker Sialyl-Tn.
  • The study was led by Richard Schwab, MD, and Ajit Varki, MD, at the UC San Diego Moores Cancer Center and the UCSD Glycobiology Research and Training Center.
  • The study was funded by the National Cancer Institute and Sialix, Inc., which has exclusive rights to commercialize the biomarker and therapeutic applications of the research.

Statistics:

  • 7/25/10: The date of a previous study by Dr. Varki and his colleagues published in Nature Biotechnology.
  • 385: The number of human blood samples sampled in the study.
  • 100%: The percentage of patients with carcinomas that have elevated levels of antibodies to one specific Neu5Gc-containing sugar chain that incorporates into the cancer marker Sialyl-Tn.
  • 50%: The concentration of purified human anti-Neu5Gc antibodies required to kill Neu5Gc-expressing mouse or human tumors.

Sources:

  • Release: "A Cancer Marker and Treatment in One? UC San Diego Researchers Find Promise in Non-Human Sialic Acid Antibodies."
  • Cancer Research
  • Nature Biotechnology
  • UCSD Glycobiology Research and Training Center and UCSD Moores Cancer Center
  • Sialix, Inc.